Droplette is a technology company.
Droplette has raised $21.0M across 1 funding round.
Droplette has raised $21.0M in total across 1 funding round.
Droplette has raised $21.0M in total across 1 funding round.
Droplette's investors include Victress Capital.
Droplette is a beauty tech startup that builds an at-home skincare system featuring a patented device and proprietary serum capsules, delivering pharmaceutical-grade ingredients deep into the skin via a high-velocity mist without needles or pain[1][2][4][5]. It serves skincare consumers seeking advanced anti-aging and hydration solutions, solving the key problem of topical products' inability to penetrate the skin barrier effectively—achieving 20X better delivery and clinically proven results like 94% improved hydration and 87% reduction in fine lines[1][4][5]. The company has shown growth momentum through a $15.4 million Series B in 2021 to expand manufacturing and markets, NASA/NIH backing, and strong consumer reviews[2][7].
Droplette was founded in 2017 by MIT-trained engineers Madhavi Gavini (CEO) and Rathi Srinivas, who pivoted medical device technology—originally developed for treating rare skin diseases and backed by NASA and NIH—into consumer skincare[2][3][7]. The core innovation emerged from research on transdermal delivery of large biomolecules like nucleic acids using a portable, contact-free system combining a piezoelectric transducer and pneumatic diaphragm pump, tested in vitro, in vivo, and human studies[3]. Early traction included peer-reviewed publications, US patents (e.g., US 9,700,686 B2), partnerships like the US Army for dermatological applications, and a shift to direct-to-consumer sales of the device and serums[2][3][7].
Droplette rides the beauty tech wave merging consumer skincare with medtech innovations like transdermal drug delivery, capitalizing on demand for needle-free, efficacious at-home alternatives to in-office treatments amid rising clean beauty and personalization trends[2][3][7]. Timing aligns with post-pandemic self-care booms and advancements in piezo-pneumatic tech, enabling scalable consumer access to pharma-grade results previously limited to clinics or labs[1][2][8]. Market forces like aging populations, e-commerce growth, and investor interest (e.g., Series B from Victress Capital) favor it, while its medical roots position it to influence ecosystems from cosmetics to gene therapy and inflammatory skin treatments[2][3].
Droplette is poised to expand its skincare lineup, automate capsule production, and enter new markets, potentially evolving into therapeutics with its versatile platform for drug/nucleic acid delivery[2][3]. Trends like AI-personalized beauty, sustainable biotech, and regulatory nods for at-home med devices will shape its path, amplifying influence in consumer health. As the pioneer in painless deep-skin infusion, it redefines "skincare on a deeper level," turning medical breakthroughs into daily rituals for transformative results[1][4].
Droplette has raised $21.0M across 1 funding round. Most recently, it raised $21.0M Series B in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $21.0M Series B | Victress Capital |